CN115073375B - Method for preparing sinomenine hydrochloride - Google Patents
Method for preparing sinomenine hydrochloride Download PDFInfo
- Publication number
- CN115073375B CN115073375B CN202210889638.XA CN202210889638A CN115073375B CN 115073375 B CN115073375 B CN 115073375B CN 202210889638 A CN202210889638 A CN 202210889638A CN 115073375 B CN115073375 B CN 115073375B
- Authority
- CN
- China
- Prior art keywords
- solvent
- sinomenine hydrochloride
- water
- extraction
- extracting solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- INYYVPJSBIVGPH-UHFFFAOYSA-N 14-episinomenine Natural products C1CN(C)C2CC3=CC=C(OC)C(O)=C3C31C2C=C(OC)C(=O)C3 INYYVPJSBIVGPH-UHFFFAOYSA-N 0.000 title claims abstract description 84
- REKJPVUFKQYMHW-UHFFFAOYSA-N 2-methyl-4-(trifluoromethyl)-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NC(C(F)(F)F)=C(C(O)=O)S1 REKJPVUFKQYMHW-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 39
- 239000002904 solvent Substances 0.000 claims abstract description 61
- 239000000463 material Substances 0.000 claims abstract description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 54
- 238000000605 extraction Methods 0.000 claims abstract description 50
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000013078 crystal Substances 0.000 claims abstract description 21
- 238000005406 washing Methods 0.000 claims abstract description 19
- 239000012071 phase Substances 0.000 claims abstract description 18
- 230000003113 alkalizing effect Effects 0.000 claims abstract description 16
- 230000002378 acidificating effect Effects 0.000 claims abstract description 10
- 239000007791 liquid phase Substances 0.000 claims abstract description 9
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical group COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 50
- 239000012046 mixed solvent Substances 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- INYYVPJSBIVGPH-QHRIQVFBSA-N Sinomenine Chemical compound C([C@@H]1N(CC2)C)C3=CC=C(OC)C(O)=C3[C@@]32[C@@H]1C=C(OC)C(=O)C3 INYYVPJSBIVGPH-QHRIQVFBSA-N 0.000 claims description 26
- RARWEROUOQPTCJ-RBUKOAKNSA-N cepharamine Natural products C1CC2=CC=C(OC)C(O)=C2[C@@]2(CCN3C)[C@]13C=C(OC)C(=O)C2 RARWEROUOQPTCJ-RBUKOAKNSA-N 0.000 claims description 26
- 229930002966 sinomenine Natural products 0.000 claims description 26
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 25
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 17
- 239000000920 calcium hydroxide Substances 0.000 claims description 17
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 17
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 15
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 15
- 238000010298 pulverizing process Methods 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 238000004904 shortening Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 48
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 238000001914 filtration Methods 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 239000008213 purified water Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 10
- 238000001035 drying Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000010992 reflux Methods 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 6
- 238000005191 phase separation Methods 0.000 description 5
- 238000000638 solvent extraction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000009395 Zhengqing Fengtongning Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 231100000003 human carcinogen Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- AZJCKNFNGHEEES-UHFFFAOYSA-N CCCCCCCC.C1(=CC=CC=C1)OC Chemical compound CCCCCCCC.C1(=CC=CC=C1)OC AZJCKNFNGHEEES-UHFFFAOYSA-N 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- AXVVWZONCVUAPP-QULPKBGFSA-N Disinomenine Chemical compound C([C@@H]1[C@@H](N(CC2)C)C3)=C(OC)C(=O)C[C@]21C1=C3C(C2=C3C[C@H]4[C@H]5C=C(C(C[C@@]5(CCN4C)C3=C(O)C(OC)=C2)=O)OC)=CC(OC)=C1O AXVVWZONCVUAPP-QULPKBGFSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001506304 Kadsura japonica Species 0.000 description 1
- RYPHKZUVFXPUMU-PDSXEYIOSA-N Magnolone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)[C@H]1[C@H](CO)[C@@H](C=2C=C3OCOC3=CC=2)OC1 RYPHKZUVFXPUMU-PDSXEYIOSA-N 0.000 description 1
- 241000218164 Menispermaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 101710186426 Spiniferin Proteins 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- BMGOOCPGRUYFFT-UHFFFAOYSA-N anisole heptane Chemical compound CCCCCCC.COc1ccccc1 BMGOOCPGRUYFFT-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- GQTWBRFNZHWIEF-WDYWJOCVSA-N disinomenine Natural products COC1=C[C@@H]2[C@@H]3Cc4c(c(OC)cc(O)c4[C@]2(CCN3C)CC1=O)c5c6C[C@H]7[C@H]8C=C(OC)C(=O)C[C@@]8(CCN7C)c6c(O)cc5OC GQTWBRFNZHWIEF-WDYWJOCVSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- FJXKIGDEXMHOCZ-UHFFFAOYSA-N magnolone Natural products COc1ccc(cc1OC)C(O)C2COC(C2CO)c3ccc4OCOc4c3 FJXKIGDEXMHOCZ-UHFFFAOYSA-N 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 231100000804 nongenotoxic Toxicity 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The application discloses a method for preparing sinomenine hydrochloride, which is characterized by comprising the following steps: (1) taking caulis sinomenii, crushing, alkalizing and stacking; (2) Adding a solvent into the alkalized medicinal materials for extraction, and collecting an extracting solution; (3) Washing the extracting solution with water, separating the liquid phase and discarding the water phase; (4) Adding hydrochloric acid into the water-washed extracting solution until the system is acidic, and obtaining sinomenine hydrochloride crystals. The application has the outstanding advantages of few process steps, and the sinomenine hydrochloride crystal can be prepared by only three steps after alkalizing medicinal materials, thereby being beneficial to reducing the loss of sinomenine hydrochloride in the pharmaceutical process, shortening the production period and improving the production efficiency.
Description
Technical Field
The application belongs to the field of medicines, and relates to a method for preparing sinomenine hydrochloride.
Background
The caulis Sinomenii is a dry rattan of Sinomenii and Sinomenii of Menispermaceae, such as Sinomenii caulis, herba Aristolochiae Mollissimae, etc. As a traditional medicinal plant, the Chinese medicinal composition has remarkable effects of resisting inflammation, promoting urination, dispelling wind-dampness and the like. Caulis Sinomenii contains abundant alkaloids such as sinomenine, bisinomenine, tetrahydropalmatine, spiniferin, kadsura longepedunculata, magnolone, etc., wherein sinomenine is the main alkaloid monomer in caulis Sinomenii, and has been used as index component of caulis Sinomenii in Chinese pharmacopoeia of 2020 edition. Sinomenine has various pharmacological activities, and can be used for treating arrhythmia, rheumatic or rheumatoid arthritis, neuralgia, etc. by using its hydrochloric acid preparation such as ZHENGQINGFENGTONGNING tablet, ZHENGQINGFENGTONGNING injection, and sinomenine hydrochloride enteric coated tablet.
The extraction and preparation process of sinomenine hydrochloride in the current industry is mainly divided into two modes of solvent reflux extraction and preparation process and acid water extraction and preparation process. Wherein, the solvent reflux extraction preparation process is divided into a direct reflux process and an alkalization reflux process. The sinomenine hydrochloride can be obtained by directly refluxing with ethanol as solvent and performing microfiltration, concentration, multiple times of pH adjustment, solvent extraction, reduced pressure concentration, drying and the like for more than 10 steps. The alkalizing reflux often comprises the following steps: alkalizing the medicinal materials, extracting under reflux with solvent, concentrating to obtain crude product, re-dissolving with water, adjusting pH, adsorbing with activated carbon, and crystallizing. The acid water extraction preparation process comprises the steps of acid water impregnation, multiple pH adjustment, alkali precipitation, solvent extraction, back extraction, crystallization and the like. The comprehensive view is that the prior process adopted in industry has complicated steps and long flow and needs to be improved. In addition, the extraction preparation process has low selectivity to sinomenine by using solvents or extracting agents such as hydrochloric acid aqueous solution and the like in the extraction step, the obtained extracting solution has more impurities, and due to the limitation that the extracting agents can be mutually dissolved with water, the extracting agents can not be directly used for removing impurities in a water washing way, and further purification is required by taking other solvents as extracting agents, so that the problems of a plurality of subsequent purification and refining steps, high cost and the like are caused. Therefore, a new process for extracting sinomenine hydrochloride with simple subsequent purification mode, short flow and low cost still needs to be developed.
Disclosure of Invention
The application aims to provide a method for preparing sinomenine hydrochloride, aiming at the problems of complex purification process, long flow and the like in the existing sinomenine hydrochloride extraction and preparation process.
The application aims at realizing the following technical scheme:
a method for preparing sinomenine hydrochloride, comprising the steps of:
(1) Pulverizing caulis Sinomenii, alkalizing and stacking;
(2) Adding a solvent into the alkalized medicinal materials for extraction, and collecting an extracting solution;
(3) Washing the extracting solution with water, separating the liquid phase and discarding the water phase;
(4) Adding hydrochloric acid into the water-washed extracting solution until the system is acidic, and obtaining sinomenine hydrochloride crystals.
Further, the solvent comprises chloroform, or anisole, or methyl isobutyl ketone and anisole.
Further, when the solvent is a mixed solvent, the methyl isobutyl ketone accounts for less than 50% of the volume fraction of the mixed solvent.
Preferably, when the solvent is added, the ratio of the volume (mL) of the solvent to the mass (g) of the medicinal material is 5/1-10/1.
The extraction time is 0.5-2h.
Preferably, the number of extraction times is 2-3.
Further preferably, when the sinomenine extracting solution is washed by the water, the volume ratio of the water phase to the extracting solution is 1:2-1:4.
Further, the mass ratio of the medicinal materials to the calcium hydroxide is 10-30:1-6; the concentration of the hydrochloric acid is 0.5-10 mol/L.
Preferably, the mass ratio of the medicinal materials to the calcium hydroxide is 15-25:2-4; the concentration of the hydrochloric acid is 1-8 mol/L.
Furthermore, the method for preparing sinomenine hydrochloride further comprises a purification step, wherein the solid obtained after the reaction is washed by adding ethanol and dried to obtain the sinomenine hydrochloride.
The application has the advantages that the anisole, chloroform and the mixed solvent of anisole and methyl isobutyl ketone have the advantages of strong extraction capacity and high selectivity. The solvent is not only an extractant of sinomenine, but also can utilize the characteristic of non-mutual solubility of sinomenine and water, and a water washing impurity removing mode can be directly adopted in the follow-up process, so that the purification difficulty is obviously reduced, the process flow is shortened, the impurity content of the obtained extract is low, and the purity of sinomenine is high. The application has the outstanding advantages of few process steps, and the sinomenine hydrochloride crystal can be prepared by only three steps after alkalizing medicinal materials, thereby being beneficial to reducing the loss of sinomenine hydrochloride in the pharmaceutical process, shortening the production period and improving the production efficiency. The organic solvent adopted by the application can be reused after being regenerated in a distillation mode and the like, thereby being beneficial to controlling the cost. The sinomenine hydrochloride crystal obtained by the application is a crude product, and high-purity sinomenine hydrochloride refined products can be obtained by recrystallization. In general, the application can obviously shorten the production process flow of sinomenine hydrochloride, improve the overall production efficiency, reduce the cost and have good industrial prospect.
The extraction method and the extraction solvent are technical innovations, not only can use extremely toxic solvents such as benzene and the like be avoided, but also high-purity sinomenine hydrochloride can be prepared.
Detailed Description
The following experimental examples and examples serve to further illustrate but not limit the application.
Experimental example 1: research on the effect of single solvent extraction of sinomenine in sinomenine
15g of the powdered sinomenine medicinal material powder is weighed, 6g of calcium hydroxide and 22.5mL of purified water are added into the medicinal material, and the mixture is stirred uniformly, so that the medicinal material is wetted, alkalized and stacked for 3 hours. Measuring 120mL of solvent, adding into the alkalified medicinal materials, extracting at corresponding temperature for 1 hr (solvent with boiling point higher than 85deg.C is uniformly heated at 85deg.C for extraction, solvent with boiling point lower than 85deg.C is uniformly heated at room temperature 25 deg.C), and filtering to obtain residue. The purity and extraction amount of sinomenine in the extract were measured, and the specific results are shown in table 1.
TABLE 1 Single solvent extraction Effect
As can be seen from Table 1, sinomenine was not extracted from both cyclohexane and n-heptane. From the purity point of view, the purity of chloroform and anisole is highest, the purity of ethyl acetate and methyl isobutyl ketone is next highest, and the purity of acetic acid is lowest. The extraction amount of chloroform and anisole is the highest, and the extraction amount of benzyl alcohol and other solvents are less. Therefore, sinomenine extracted by chloroform and anisole has high purity and large extraction quantity.
Experimental example 2: research on the effect of extracting sinomenine from sinomenine by mixed solvent
Taking 20g of the powdered sinomenine, adding 3g of calcium hydroxide powder and 20mL of purified water into the drug, alkalizing and stacking for 3h. Adding 160mL of mixed organic solvent into the alkalized medicinal materials, stirring and extracting at 75 ℃ for 45min, filtering the residues, and preserving the filtrate; 140mL of mixed organic solvent is added into the filter residue, the mixture is stirred and extracted for 45min at 75 ℃, then the mixture is filtered, the two extracts are combined, and the purity and the extraction amount of the extracts are detected, and the results are shown in Table 2.
TABLE 2 Mixed solvent extraction Effect
In the comprehensive view, the three groups of mixed solvents have better extraction effect, water is added into the three groups of extracting solutions according to the volume ratio of 1:3 for water washing, then 6mL of concentrated hydrochloric acid with the concentration of 2mol/L is added, the system is acidic, the mixing and stirring are carried out, the solid is filtered, a small amount of ethanol is added for washing, and the sinomenine hydrochloride crystals with the purities of 48.5%, 14.3% and 73.25% in terms of mass fraction are obtained after drying. The sinomenine hydrochloride crystal obtained by the mixed solvent composed of n-heptane, n-octane and anisole has low purity, and the methyl isobutyl ketone used as the solvent mixed with anisole can reduce the emulsification degree, and the purity of the proposed sinomenine hydrochloride crystal is higher.
Experimental example 3: contrast of alkalization effects of medicinal materials
The effect of the medicinal material alkalization step related by the application is studied, and experiments are carried out under the conditions of medicinal material alkalization and non-alkalization respectively:
alkalization: weighing 30g of medicinal materials, adding 4.0435g of calcium hydroxide powder, adding 30mL of water, stirring uniformly to moisten the medicinal materials, alkalizing and stacking for 4 hours, directly adding 150mL of anisole (the volume ratio of the solvent to the mass of the medicinal materials is 5/1), stirring and extracting for 1 hour at 90 ℃, and filtering while the medicinal materials are hot to obtain anisole extract. The extraction amount of sinomenine in the extracting solution is measured to be 16.07mg/g of medicinal material.
Not alkalized: weighing 40g of caulis sinomenii, adding 200mL of solvent (the volume ratio of the solvent to the mass ratio of the drug is 5/1), stirring and heating at 90 ℃ for extraction for 1h, and filtering while the mixture is hot to obtain anisole extract. The extraction amount of sinomenine in the extracting solution is measured to be 11.28mg/g of medicinal material.
Experimental results show that the extraction amount of the medicinal materials is obviously improved after the medicinal materials are alkalized, so that the step of alkalizing the medicinal materials is necessary to be reserved.
Experimental example 4: comparison of the extraction and preparation process of sinomenine hydrochloride
The present application was compared laterally with the three processes currently most widely used in industry in terms of solvent toxicity, number of process steps, as shown in table 3. Residual solvents are classified into three categories in the ICH Q3 guidelines: the class 1 solvent is a solvent to be avoided, namely known human carcinogens, strong suspected human carcinogens and environmental hazards; class 2 solvents are solvents that should be limited to use in formulations, i.e., non-genotoxic animal carcinogens, or may cause other irreversible toxicity (e.g., neurotoxicity or teratogenicity), or may have other serious but reversible toxicity; class 3 solvents are solvents with low potential toxicity, i.e., solvents with a low risk of human health hazard. In the process development stage, 3 types of solvents should be selected preferentially, 2 types of solvents are controlled, and 1 type of solvents are avoided to the greatest extent. The solvents involved in the application are in class 2 and class 3. In addition, the application has the outstanding characteristics of short process flow, and the sinomenine hydrochloride crystal can be obtained by only 4 steps, and compared with other industrial processes, the process flow is shortened by more than 50%, the product loss is reduced, the production efficiency is improved, and the production cost is reduced.
In conclusion, compared with the existing process, the application has obvious improvement and improvement on solvent toxicity and process flow, accords with the green chemical concept, and has good industrial application prospect.
Table 3 comparison of sinomenine hydrochloride extraction and preparation process
Comparative example 1: extracting by using n-heptane-anisole as a mixed solvent:
pulverizing caulis Sinomenii, and weighing 40g of pulverized caulis Sinomenii. 6.0053g of calcium hydroxide and 40mL of purified water are added into the medicinal materials, and the mixture is stirred uniformly, so that the medicinal materials are wetted, alkalized and stacked for 3 hours. 224mL anisole and 56mL heptane were measured and mixed solvent for the first extraction was prepared. Adding mixed solvent into the alkalized medicinal materials, stirring and extracting at 75deg.C for 45min, and filtering the residues. 192mL anisole and 48mL heptane were measured and mixed solvent for the second extraction was prepared. Adding the mixed solvent for the second extraction into the extracted medicinal materials, stirring at 75deg.C for 45min, and filtering to obtain residue. Combining the two extracting solutions to finally obtain 450mL sinomenine extracting solution. 150mL of purified water is taken to wash the extract, shaking is carried out fully, standing is carried out for phase separation, and the water phase is discarded. Adding 8mL of concentrated hydrochloric acid with the concentration of 3mol/L into the water-washed extracting solution, mixing and stirring, filtering the solid, adding a small amount of ethanol for washing, and drying to obtain sinomenine hydrochloride crystals with the purity of 56.25 percent in mass fraction.
Comparative example 2: extracting with n-octane-anisole as a mixed solvent:
pulverizing caulis Sinomenii, and weighing 20g of pulverized caulis Sinomenii. 3.0013g of calcium hydroxide and 30mL of purified water are added into the medicinal materials, and the mixture is stirred uniformly, so that the medicinal materials are wetted, alkalized and stacked for 3 hours. 98mL anisole and 42mL heptane were measured and mixed solvent for the first extraction was prepared. Adding mixed solvent into the alkalized medicinal materials, stirring and extracting at 75deg.C for 45min, and filtering the residues. 84mL anisole and 36mL heptane were measured and mixed solvent for the second extraction was prepared. Adding the mixed solvent for the second extraction into the extracted medicinal materials, stirring at 75deg.C for 45min, and filtering to obtain residue. Combining the two extracting solutions to finally obtain 258mL sinomenine extracting solution. 86mL of purified water is measured to wash the extract, shaking is carried out fully, standing is carried out for phase separation, and the water phase is discarded. Adding 6mL of concentrated hydrochloric acid with the concentration of 2mol/L into the water-washed extracting solution, mixing and stirring, filtering the solid, adding a small amount of ethanol for washing, and drying to obtain sinomenine hydrochloride crystals with the purity of 13.20 percent in mass fraction.
Example 1
Pulverizing caulis Sinomenii, and weighing 35g of pulverized caulis Sinomenii. 5.2511g of calcium hydroxide and 35mL of purified water are added into the medicinal materials, and the mixture is stirred uniformly, so that the medicinal materials are wetted, alkalized and stacked for 4 hours. 200mL of chloroform was measured and added to the alkalized medicinal material, and the mixture was stirred and extracted at room temperature for 45 minutes, and the residue was filtered. Repeating the above operation, extracting twice, and finally combining the three extractive solutions to obtain 556mL of extractive solution. 278mL of purified water is measured to wash the extract, shaking is carried out fully, standing is carried out for phase separation, and the water phase is discarded. Adding 10mL of concentrated hydrochloric acid with the concentration of 2.4mol/L into the water-washed extracting solution, mixing and stirring, filtering the solid, adding a small amount of ethanol for washing, and drying to obtain sinomenine hydrochloride crystals with the purity of 90.1 percent in terms of mass fraction.
Example 2
Pulverizing caulis Sinomenii, and weighing 30g of pulverized caulis Sinomenii. 6.0412g of calcium hydroxide and 30mL of purified water are added into the medicinal materials, and the mixture is stirred uniformly, so that the medicinal materials are wetted, alkalized and stacked for 2 hours. 300mL of anisole is measured and added into the alkalized medicinal materials, the mixture is stirred and extracted for 45 minutes at 90 ℃, and the residues are filtered. Repeating the above operation, extracting twice, and finally combining the three extractive solutions to obtain 550mL of extractive solution. The extract was washed with 137.5mL of purified water, shaken well and then allowed to stand for phase separation, and the aqueous phase was discarded. Adding 9mL of concentrated hydrochloric acid with the concentration of 2mol/L into the water-washed extracting solution, mixing and stirring, filtering the solid, adding a small amount of ethanol for washing, and drying to obtain sinomenine hydrochloride crystals with the purity of 88.52 percent in mass fraction.
Example 3
Pulverizing caulis Sinomenii, and weighing 40g of pulverized caulis Sinomenii. 6.0180g of calcium hydroxide and 30mL of purified water are added into the medicinal materials, and the mixture is stirred uniformly, so that the medicinal materials are wetted, alkalized and stacked for 3 hours. 140mL anisole and 140mL methyl isobutyl ketone (1:1) are measured to prepare a mixed solvent for the first extraction. Adding mixed solvent into the alkalized medicinal materials, stirring and extracting at 75deg.C for 45min, and filtering the residues. 120mL anisole and 120mL methyl isobutyl ketone (1:1) are measured to prepare a mixed solvent for the second extraction. Adding the mixed solvent for the second extraction into the extracted medicinal materials, stirring at 75deg.C for 45min, and filtering to obtain residue. The two extracts were combined to finally obtain 480mL of extract. 160mL of purified water is measured to wash the extract, shaking is carried out fully, standing is carried out for phase separation, and the water phase is discarded. Adding 8mL of concentrated hydrochloric acid with the concentration of 3mol/L into the water-washed extracting solution, mixing and stirring, filtering the solid, adding a small amount of ethanol for washing, and drying to obtain sinomenine hydrochloride crystals with the purity of 88.75 percent in mass fraction.
Example 4
A method for preparing sinomenine hydrochloride, comprising the steps of:
(1) Pulverizing caulis Sinomenii, alkalizing and stacking;
(2) Adding a solvent into the alkalized medicinal materials for extraction, and collecting an extracting solution;
(3) Washing the extracting solution with water, separating the liquid phase and discarding the water phase;
(4) Adding hydrochloric acid into the water-washed extracting solution until the system is acidic to obtain sinomenine hydrochloride crystals;
the solvent is chloroform.
Example 5
A method for preparing sinomenine hydrochloride, comprising the steps of:
(1) Pulverizing caulis Sinomenii, alkalizing and stacking;
(2) Adding a solvent into the alkalized medicinal materials for extraction, and collecting an extracting solution;
(3) Washing the extracting solution with water, separating the liquid phase and discarding the water phase;
(4) Adding hydrochloric acid into the water-washed extracting solution until the system is acidic to obtain sinomenine hydrochloride crystals; the solvent is anisole;
when the solvent is added, the ratio of the volume (mL) of the solvent to the mass (g) of the medicinal material is 6/1; when the sinomenine extracting solution is washed by the water, the volume ratio of the water phase to the extracting solution is 1:3;
the method for preparing sinomenine hydrochloride further comprises a purification step, wherein the solid obtained after the reaction is washed by adding ethanol and dried to obtain the sinomenine hydrochloride.
Example 6
A method for preparing sinomenine hydrochloride, comprising the steps of:
(1) Pulverizing caulis Sinomenii, alkalizing and stacking;
(2) Adding a solvent into the alkalized medicinal materials for extraction, and collecting an extracting solution;
(3) Washing the extracting solution with water, separating the liquid phase and discarding the water phase;
(4) Adding hydrochloric acid into the water-washed extracting solution until the system is acidic, and obtaining sinomenine hydrochloride crystals.
The solvent is methyl isobutyl ketone and anisole; methyl isobutyl ketone accounts for 20 percent of the volume fraction of the mixed solvent;
when the solvent is added, the ratio of the volume (mL) of the solvent to the mass (g) of the medicinal material is 7/1;
the extraction time is 1h.
Preferably, the extraction times are 2 times;
when the sinomenine extracting solution is washed by the water, the volume ratio of the water phase to the extracting solution is 1:2.
Example 7
A method for preparing sinomenine hydrochloride, comprising the steps of:
(1) Pulverizing caulis Sinomenii, alkalizing and stacking;
(2) Adding a solvent into the alkalized medicinal materials for extraction, and collecting an extracting solution;
(3) Washing the extracting solution with water, separating the liquid phase and discarding the water phase;
(4) Adding hydrochloric acid into the water-washed extracting solution until the system is acidic, and obtaining sinomenine hydrochloride crystals.
The mass ratio of the medicinal materials to the calcium hydroxide is 20:2;
the method also comprises a purification step, wherein the solid obtained after the reaction is washed by adding ethanol and dried to obtain the catalyst; the solvent is methyl isobutyl ketone and anisole; the methyl isobutyl ketone accounts for 10 percent of the volume fraction of the mixed solvent.
Example 8
A method for preparing sinomenine hydrochloride, comprising the steps of:
(1) Pulverizing caulis Sinomenii, alkalizing and stacking;
(2) Adding a solvent into the alkalized medicinal materials for extraction, and collecting an extracting solution;
(3) Washing the extracting solution with water, separating the liquid phase and discarding the water phase;
(4) Adding hydrochloric acid into the water-washed extracting solution until the system is acidic to obtain sinomenine hydrochloride crystals;
chloroform as the solvent;
when the solvent is added, the ratio of the volume (mL) of the solvent to the mass (g) of the medicinal material is 5.5/1;
the extraction time is 0.8h.
Preferably, the number of extraction times is 3.
When the sinomenine extracting solution is washed by the water, the volume ratio of the water phase to the extracting solution is 1:2.5;
the mass ratio of the medicinal materials to the calcium hydroxide is 25:2; the concentration of the hydrochloric acid is 3mol/L.
Example 9 a process for preparing sinomenine hydrochloride comprising the steps of:
(1) Pulverizing caulis Sinomenii, alkalizing and stacking;
(2) Adding a solvent into the alkalized medicinal materials for extraction, and collecting an extracting solution;
(3) Washing the extracting solution with water, separating the liquid phase and discarding the water phase;
(4) Adding hydrochloric acid into the water-washed extracting solution until the system is acidic, and obtaining sinomenine hydrochloride crystals.
The solvent is methyl isobutyl ketone and anisole; methyl isobutyl ketone accounts for 45% of the volume fraction of the mixed solvent; when the solvent is added, the ratio of the volume (mL) of the solvent to the mass (g) of the medicinal material is 9/1; the extraction time is 2 hours; when the sinomenine extracting solution is washed by the water, the volume ratio of the water phase to the extracting solution is 1:3.5; the mass ratio of the medicinal materials to the calcium hydroxide is that the method also comprises a purification step, and the solid obtained after the reaction is added with ethanol for washing, and the ratio of the ethanol to the calcium hydroxide is 22:2; the concentration of the hydrochloric acid is 3mol/L; the sinomenine hydrochloride is prepared after drying.
Other embodiments of the application will be apparent to those skilled in the art from consideration of the specification and practice of the application disclosed herein. This application is intended to cover any variations, uses, or adaptations of the application following, in general, the principles of the application and including such departures from the present disclosure as come within known or customary practice within the art to which the application pertains. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the application being indicated by the following claims. It will be understood that the application is not limited to what has been described above and that various modifications and changes may be made without departing from the scope thereof. The scope of the application is limited only by the appended claims.
Claims (8)
1. A method for preparing sinomenine hydrochloride, comprising the steps of:
(1) Pulverizing caulis Sinomenii, alkalizing and stacking;
(2) Adding a solvent into the alkalized medicinal materials for extraction, and collecting an extracting solution;
(3) Washing the extracting solution with water, separating the liquid phase and discarding the water phase;
(4) Adding hydrochloric acid into the water-washed extracting solution until the system is acidic to obtain sinomenine hydrochloride crystals; the solvent is selected from anisole, or a mixed solvent of methyl isobutyl ketone and anisole; when the solvent is added, the ratio of the volume mL of the solvent to the mass g of the medicinal material is 5/1-10/1; when the solvent is a mixed solvent, the methyl isobutyl ketone accounts for less than 50 percent of the volume fraction of the mixed solvent.
2. The method for preparing sinomenine hydrochloride according to claim 1, wherein the extraction time is 0.5 to 2 hours.
3. The method for preparing sinomenine hydrochloride according to claim 1, wherein the number of extraction is 2 to 3.
4. The method for preparing sinomenine hydrochloride according to claim 1, wherein the volume ratio of the aqueous phase to the extract is 1:2-1:4 when the sinomenine extract is washed with water.
5. The method for preparing sinomenine hydrochloride according to claim 1, wherein the base used for the alkalization is calcium hydroxide.
6. The method for preparing sinomenine hydrochloride according to claim 5, wherein the mass ratio of the medicinal material to the calcium hydroxide is 10-30:1-6; the concentration of the hydrochloric acid is 0.5-10 mol/L 。
7. The method for preparing sinomenine hydrochloride according to claim 6, wherein the mass ratio of the medicinal material to the calcium hydroxide is 15-25:2-4; the concentration of the hydrochloric acid is 1-8 mol/L.
8. The method for preparing sinomenine hydrochloride according to claim 1, further comprising a purification step, wherein the solid obtained after the reaction is washed with ethanol and dried.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210889638.XA CN115073375B (en) | 2022-07-27 | 2022-07-27 | Method for preparing sinomenine hydrochloride |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210889638.XA CN115073375B (en) | 2022-07-27 | 2022-07-27 | Method for preparing sinomenine hydrochloride |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115073375A CN115073375A (en) | 2022-09-20 |
CN115073375B true CN115073375B (en) | 2023-12-01 |
Family
ID=83243468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210889638.XA Active CN115073375B (en) | 2022-07-27 | 2022-07-27 | Method for preparing sinomenine hydrochloride |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115073375B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150085968A (en) * | 2014-01-17 | 2015-07-27 | 주식회사 엘지생활건강 | Cosmetic or pharmaceutical composition for promoting hair growth containing Sinomenine Hydrochloride |
-
2022
- 2022-07-27 CN CN202210889638.XA patent/CN115073375B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150085968A (en) * | 2014-01-17 | 2015-07-27 | 주식회사 엘지생활건강 | Cosmetic or pharmaceutical composition for promoting hair growth containing Sinomenine Hydrochloride |
Non-Patent Citations (1)
Title |
---|
盐酸青藤碱的提取分离工艺研究;温迪一;《中国优秀硕士学位论文全文数据库 工程科技I辑》(第2022年第01期期);6-7 * |
Also Published As
Publication number | Publication date |
---|---|
CN115073375A (en) | 2022-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101643466B (en) | Epigallo-catechin gallate (EGCG) with high purity and preparation method thereof | |
CN108752231B (en) | Method for extracting theanine from sweet tea and simultaneously extracting rubusoside and tea polyphenol | |
CN102212091A (en) | High-purity geniposide as well as preparation and clinical application of preparations thereof | |
CN110638837A (en) | Propolis extract and preparation method and application thereof | |
CN102423329B (en) | A kind of discoloration method of panax notoginsenoside extract | |
CN111960930A (en) | Method for separating and purifying cannabidiol from industrial cannabis sativa leaves | |
CN102002082A (en) | Method for preparing baicalin | |
CN110818585B (en) | Separation method for simultaneously preparing five dopamine compounds from aspongopus | |
CN113648834A (en) | Ceramic membrane and preparation method and application thereof | |
CN101759756A (en) | Method for preparing ursolic acid from rosemary | |
JP6588072B2 (en) | Extraction and separation method of Eurycomanone from root of Tongkat ant | |
CN104127451A (en) | Method of simultaneously extracting polyphenol, flavonoids and triterpenes from pomegranate flowers | |
CN115073375B (en) | Method for preparing sinomenine hydrochloride | |
CN1982279A (en) | Preparation of shikimic acid | |
CN115703740A (en) | Preparation method of bulleyaconitine A | |
CN111171104B (en) | Method for preparing ursolic acid from rosemary oil paste by-product | |
CN113444043A (en) | Lotus leaf alkaloid and extraction and purification method thereof | |
CN103585208B (en) | Preparation method of high-quality andrographolide component | |
CN110627807A (en) | Bilobalide B raw material and preparation method thereof | |
CN102329345A (en) | Method for extracting and purifying sarmentosin in Sedum sarmentosum Bunge | |
CN104710492A (en) | Method for extracting androstenedione in bi-liquid phases system | |
CN110831953B (en) | Method for separating and purifying icariin from epimedium extract | |
CN107739306B (en) | A method for preparing refined herba Rosmarini officinalis extract | |
CN103923159B (en) | A kind of method of Hydrolysis kinetics ursolic acid from Loquat Leaf | |
CN101817778A (en) | Method for preparing indirubin from indigowoad leaves |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |